News from CROI 2015

The annual Conference on Retroviruses and Opportunistic Infections (CROI 2015) is taking place in Seattle, USA, in late February.

Our writers will be reporting on key research presented at the conference, publishing news and sending out CROI news summary bulletins by email, three during the conference week and one the following week.

“The coverage made me feel I was at the conference and I appreciate NAM's effort in sharing the bulletins.” NAM bulletin subscriber

aidsmap news from CROI 2015

HCV viral load levels during treatment and speed of decline do not predict cure with interferon-free therapy

Direct-acting antiviral regimens containing sofosbuvir (Sovaldi) and the drugs in Viekirax/Exviera were highly effective regardless of how soon hepatitis C viral load became undetectable after starting treatment, according to

Published
23 April 2015
By
Liz Highleyman
Daily PrEP leads to better adherence and protective drug levels in women

HIV-negative African women assigned to take once-daily Truvada for HIV pre-exposure prophylaxis (PrEP) achieved better adherence than those assigned to take PrEP twice weekly or before and after

Published
22 April 2015
By
Liz Highleyman
High-dose rifampicin may shorten time to TB clearance

A combination regimen containing high-dose rifampicin (also known as rifampin) was associated with faster tuberculosis (TB) bacteria culture conversion in people with drug-sensitive TB, but moxifloxacin and

Published
13 April 2015
By
Liz Highleyman
End-stage liver disease is a concern for people with HIV and hepatitis B or C co-infection

People with HIV and hepatitis B or C virus co-infection are more likely to progress to end-stage liver disease (ESLD), or liver failure, than those with HIV

Published
07 April 2015
By
Liz Highleyman
HCV sexual transmission linked to anal sex, drug use, lower CD4 count

In addition to the usual risk factors for hepatitis C virus (HCV) sexual transmission seen in most previous studies – such as anal sex and having other

Published
31 March 2015
By
Liz Highleyman
Experimental agents reverse HIV latency and help immune system fight HIV-infected cells

Researchers at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, presented data on several experimental agents that may play a role in achieving

Published
24 March 2015
By
Liz Highleyman
Early antiretroviral treatment reduces, but does not eliminate HIV reservoir

Starting antiretroviral therapy (ART) very soon after infection may limit the size of the HIV 'reservoir' and delay viral rebound after treatment interruption, according to several presentations at

Published
24 March 2015
By
Liz Highleyman
Cabotegravir and rilpivirine effective for HIV maintenance therapy at 96 weeks

An combination of two once-daily oral antiretrovirals – the next-generation integrase inhibitor cabotegravir (GSK1265744) and the approved NNRTI rilpivirine (Edurant, also in Eviplera or Complera) – was as effective

Published
19 March 2015
By
Liz Highleyman
FRAX fracture prediction tool underestimates fracture risk in people with HIV

The Fracture Risk Assessment Tool (FRAX), an online tool developed by the World Health Organization and used to help guide decisions about who to screen or treat

Published
18 March 2015
By
Theo Smart
Sustained virological response represents a long-term cure for people with hepatitis C treated with sofosbuvir

Almost all patients with hepatitis C virus (HCV) alone or HIV and HCV co-infection who achieved sustained virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin

Published
17 March 2015
By
Liz Highleyman
← First12345Next →

Email bulletins

Sign up for our conference bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.